ReaConsult — Expert Immobilier Certifié RICS au Maroc
Case study · Trade-Related Property · RICS VPGA 4

Valuing a 38-bed private clinic — Sidi Maârouf, Casablanca
RICS VPGA 4 trade-related approach

A private clinic isn't a building: it's an operating asset inseparable from its business. The RICS VPGA 4 method (Trade-Related Property), used for hotels, also applies to healthcare facilities. Here's how we valued a 38-bed clinic in Sidi Maârouf in March 2026, in the context of a sale to a regional healthcare group.

Why this case study?Morocco hosts more than 380 private clinics in 2026, with 60% concentrated in the Casablanca-Rabat axis. With AMO universal coverage and ongoing sector consolidation (local groups and Gulf investors), M&A activity on these assets is booming. But valuation remains poorly mastered: most transactions rely on revenue multiples without methodological rigour. Here's the disciplined RICS approach.

1. Methodology — why VPGA 4, not VPS 5

A private clinic exhibits all the features of a Trade-Related Property (TRP) under RICS VPGA 4:

  • Specialised asset — the building design (operating theatres, wards, ER, imaging) precludes easy alternative use.
  • Value tied to operations — market value depends on cash flows generated (consultations, hospitalisations, surgical procedures), not gross floor area. Bare-building value is materially below operating-clinic value.
  • Inseparable contents (medical FF&E, conventions, licences) — Health Ministry licences, CNSS and insurance conventions, medical staff stability are valuable in their own right.
  • Significant goodwill — clinic reputation, local catchment, loyalty of operating consultant physicians constitute intangible value.

Consequence: the EBITDA multiple method (often used by investment banks) or a 10-year EBITDA DCF are dominant approaches. RICS VPS 5 sales comparison is used for triangulation but cautiously, given the small number of public clinic transactions in Morocco.

2. The asset

  • Location: Sidi Maârouf, Casablanca, fast-densifying corridor (Mohammed V Airport, CFC 12 min away).
  • Building: 4,800 m² GFA over 3 floors + technical basement, built 2011, partial refurbishment 2022.
  • Capacity: 38 inpatient beds, 4 operating theatres, 2 recovery rooms, 24/7 ER, imaging (CT + 1.5T MRI), in-house lab and pharmacy.
  • Staff: 142 salaried (18 in-house doctors, 64 nurses, 28 paramedical, 32 admin). 47 panel consultants (surgeons, anaesthetists, specialists).
  • 2025 activity: 14,200 outpatient visits, 3,850 surgical procedures, 8,600 inpatient days, 12,100 imaging acts.
  • Conventions: CNSS (60% of revenue), CNOPS, RAMED, 7 private mutuals, AXA Assurance Maroc, Wafa Assurance.

3. Operating analysis — sector KPIs

KPIDefinitionSubject clinicMorocco sector median
Occupancy rateBeds occupied / available72%62%
Avg length of stay (ALOS)Inpatient-days / discharges3.1 d3.4 d
Revenue per bed-dayInpatient revenue / bed-days2,850 MAD2,600 MAD
EBITDA marginEBITDA / revenue22%15-18%
Personnel cost / revenueSalary cost / revenue38%42%
Case Mix Index (CMI)Procedure complexity weighting1.181.00 (reference)
2025 revenue72.5 M MAD

Diagnosis: the clinic outperforms its segment on 4 out of 6 KPIs (occupancy, margin, revenue per bed-day, case mix), reflecting a mid-to-high surgical positioning and good management. The 5-year projection can rely on stable indicators.

4. Method 1 — 10-year EBITDA DCF

  • Year 0 (2025): EBITDA 15.9 M MAD (revenue 72.5 × 22% margin).
  • Revenue growth: +4.5%/year (AMO universal coverage rollout + Casablanca demographic growth + case mix uplift).
  • Margin trajectory: 22% maintained for 5 years, slight pressure to 21% from Y6 (sector competition).
  • Run-rate capex: 4% of revenue for medical FF&E renewal.
  • Cyclical capex: 18 M MAD in Y7 for OR refurbishment (minimally invasive tech, hybrid theatres).
  • Working-capital change: +0.8% of revenue (long CNSS payment cycle).
  • WACC: 11.5% (MAD risk-free 4.2% + equity risk premium 5.5% + Morocco healthcare-specific premium 1.8%).
  • Terminal value: Y10 EBITDA × 7.5x exit multiple (anchored on 2022-2025 sector deals).

DCF result: Enterprise Value (EV) ≈ 82 M MAD. Less estimated net debt of 4 M MAD → Equity Value ≈ 78 M MAD.

5. Method 2 — Sector EBITDA multiple

Multiple calibrated on 4 comparable transactions 2022-2025 (30-60 bed clinics Casa/Rabat, anonymised):

  • Deal A (45 beds, Casa, 2024): EV/EBITDA = 6.8x
  • Deal B (32 beds, Rabat, 2023): EV/EBITDA = 5.5x
  • Deal C (52 beds, Casa, 2025): EV/EBITDA = 7.2x (high case mix, similar to subject)
  • Deal D (28 beds, Casa, 2022): EV/EBITDA = 5.1x

Selected multiple: 6.8x (median adjusted up for higher case mix and margin). Y0 EBITDA 15.9M × 6.8 = EV ≈ 108 M MAD. Higher than the DCF — likely reflects optimism in 2024-2025 deals (competition for quality assets).

6. Method 3 — Bare-building DRC (floor check)

Pure cost approach (DRC, RICS VPGA 5), to verify the « floor value » if the clinic ceased operations:

  • Replacement cost new: 4,800 m² × 12,500 MAD/m² = 60 M MAD
  • Physical depreciation 35% (15 years, partial reno): -21 M MAD
  • Building residual value: 39 M MAD
  • Land (1,200 m² on corridor): 5,500 MAD/m² × 1,200 = 6.6 M MAD
  • Total DRC bare-building: ~46 M MAD

The 32 M MAD gap between DCF value (78M) and bare DRC (46M) precisely measures the operating goodwill — licences, medical FF&E, conventions, goodwill, team.

7. Synthesis — selected value range

MethodEV (M MAD)Weight
10-year EBITDA DCF8260%
Sector EBITDA multiple10830%
Bare-building DRC4610% (floor)
Selected market value (Equity)~ 82 M MAD (EV) → ~ 78 M MAD (Equity)

Range communicated to client: 75-85 M MAD for equity value. 78 M MAD selected as central reference.

8. Sensitivity tests — decisive in TRP

  • EBITDA margin — drop from 22% to 18%: EV falls from 82 to 67 M MAD (-18%).
  • Revenue growth — drop from 4.5% to 2%/year: EV falls to 70 M MAD (-15%).
  • Exit multiple / WACC — exit multiple 6x instead of 7.5x: EV falls to 75 M MAD (-9%).
  • Worst-case combined: EV ≈ 55 M MAD (-33% vs. base case).

Buyer perspective: a cautious acquirer values closer to 65-70 M MAD to preserve safety margin. An ambitious seller pushes 90-95 M, anchoring on 2024-2025 multiples. Negotiation typically lands between 70 and 85 M MAD, depending on competitive dynamics.

9. Sector-specific points (Morocco healthcare)

  • Conventions — losing a CNSS or major mutual convention can cut revenue 30-40% in months. Due diligence must verify contractual stability and renewals.
  • Health Ministry licences — transferable with operations, but require update on any significant capital change.
  • Law 131-13 on the practice of medicine and new Law 06-22 (2024 reform) of the health system — ongoing impacts on private clinic governance.
  • Key consultant physicians — a surgeon driving 25% of surgical revenue is both an asset and a risk. Post-deal retention (non-compete + earn-out) is critical to preserve value.
  • Underlying property — verify TF title, planning compliance (« healthcare » vs. zoning), absence of problematic easements. Subject clinic was on clean TF, no charges.

10. Outcome

The 52-page ReaConsult report served as the negotiation base between the founder-owner and a regional clinic group. Deal closed at 81 M MAD for 100% equity, the high end of our central range — reflecting consolidation dynamics favourable to sellers. Financed 60% bank debt (CIH Bank), 40% acquirer equity. The RICS report served as both negotiation base and bank financing document.

Related reading

Browse our full Morocco property blog or learn about our RICS service for specialised assets.

Buying or selling a clinic in Morocco?

RICS VPGA 4 trade-related valuation, DCF + multiples + DRC, healthcare due diligence. Confidential mandates.

Our RICS serviceConfidential mandate
Quick quoteContact us